The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
Top Cited Papers
Open Access
- 13 August 2009
- Vol. 339 (aug13 2), b2921
- https://doi.org/10.1136/bmj.b2921
Abstract
Objective To assess the thrombotic risk associated with oral contraceptive use with a focus on dose of oestrogen and type of progestogen of oral contraceptives available in the Netherlands. Design Population based case-control study. Setting Six participating anticoagulation clinics in the Netherlands (Amersfoort, Amsterdam, The Hague, Leiden, Rotterdam, and Utrecht). Participants Premenopausal women Main outcome measures First objectively diagnosed episodes of deep venous thrombosis of the leg or pulmonary embolism. Odds ratios calculated by cross-tabulation with a 95% confidence interval according to Woolf’s method; adjusted odds ratios estimated by unconditional logistic regression, standard errors derived from the model. Results Currently available oral contraceptives increased the risk of venous thrombosis fivefold compared with non-use (odds ratio 5.0, 95% CI 4.2 to 5.8). The risk clearly differed by type of progestogen and dose of oestrogen. The use of oral contraceptives containing levonorgestrel was associated with an almost fourfold increased risk of venous thrombosis (odds ratio 3.6, 2.9 to 4.6) relative to non-users, whereas the risk of venous thrombosis compared with non-use was increased 5.6-fold for gestodene (5.6, 3.7 to 8.4), 7.3-fold for desogestrel (7.3, 5.3 to 10.0), 6.8-fold for cyproterone acetate (6.8, 4.7 to 10.0), and 6.3-fold for drospirenone (6.3, 2.9 to 13.7). The risk of venous thrombosis was positively associated with oestrogen dose. We confirmed a high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives. Conclusions Currently available oral contraceptives still have a major impact on thrombosis occurrence and many women do not use the safest brands with regard to risk of venous thrombosis.Keywords
This publication has 42 references indexed in Scilit:
- Incidence and mortality of venous thrombosis: a population‐based studyJournal of Thrombosis and Haemostasis, 2007
- Combined oral contraceptive pills for treatment of acnePublished by Wiley ,2007
- Old and new risk factors for upper extremity deep venous thrombosisJournal of Thrombosis and Haemostasis, 2005
- Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette®): observational studies using the UK General Practice Research DatabasePharmacoepidemiology and Drug Safety, 2003
- Drug points: Thromboembolism associated with the new contraceptive YasminBMJ, 2003
- Interpretations. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risksHuman Reproduction Update, 1999
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995
- Risk Factors for Fatal Venous Thromboembolism in Young Women: A Case-Control StudyInternational Journal of Epidemiology, 1992
- Oral contraceptives and venous thromboembolism: findings in a large prospective study.BMJ, 1986